KPV
Tripeptide researched for immune modulation.
KPV
Background
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone. It has been studied for anti-inflammatory activity that appears to be independent of melanocortin receptors, with proposed intracellular actions on NF-kB signaling and uptake via the peptide transporter PepT1 in intestinal epithelium.
Preclinical models of colitis and inflammation form the bulk of the evidence; KPV is a research compound without an approved indication.
Selected literature
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331.
- Dahlman-Wright K, et al. Anti-inflammatory actions of melanocortin peptides. Annals of the New York Academy of Sciences. 1999.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
KPV is the C-terminal tripeptide fragment of alpha-MSH and has no registered pharmaceutical trademark or approved drug product. Supplied as reference material only.